Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 33305.15 
• Atom Count: 2152 
• Residue Count: 289 
• Unique protein chains: 1

4FVP

Crystal structure of the Jak2 pseudokinase domain (apo form)

• DOI: 10.2210/pdb4FVP/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): 3 


• Deposited: 2012-06-29 Released: 2012-07-25 
• Deposition Author(s): Bandaranayake, R.M., Hubbard, S.R.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.01 Å
• R-Value Free: 0.212 
• R-Value Work: 0.180 

Literature

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.

Bandaranayake, R.M., Ungureanu, D., Shan, Y., Shaw, D.E., Silvennoinen, O., Hubbard, S.R.

(2012) Nat.Struct.Mol.Biol. 19: 754-759

• PubMed: 22820988 
• DOI: 10.1038/nsmb.2348
• Primary Citation of Related Structures:  
  4FVR, 4FVQ


• PubMed Abstract: 
  

The protein tyrosine kinase JAK2 mediates signaling through numerous cytokine receptors. JAK2 possesses a pseudokinase domain (JH2) and a tyrosine kinase domain (JH1). Through unknown mechanisms, JH2 regulates the catalytic activity of JH1, and hyperactivating mutations in the JH2 region of human JAK2 cause myeloproliferative neoplasms (MPNs). We showed previously that JAK2 JH2 is, in fact, catalytically active. Here we present crystal structures of human JAK2 JH2, including both wild type and the most prevalent MPN mutant, V617F. The structures reveal that JH2 adopts the fold of a prototypical protein kinase but binds Mg-ATP noncanonically. The structural and biochemical data indicate that the V617F mutation rigidifies α-helix C in the N lobe of JH2, facilitating trans-phosphorylation of JH1. The crystal structures of JH2 afford new opportunities for the design of novel JAK2 therapeutics targeting MPNs.

---

Organizational Affiliation: 

Structural Biology Program, Kimmel Center for Biology and Medicine at the Skirball Institute, New York University School of Medicine, New York, New York, USA.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Tyrosine-protein kinase JAK2	A	289	Homo sapiens	Mutation(s): 3  Gene Names: JAK2 EC: 2.7.10.2
Find proteins for O60674 (Homo sapiens) Go to Gene View: JAK2 Go to UniProtKB:  O60674

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
GOL	A	GLYCEROL GLYCERIN; PROPANE-1,2,3-TRIOL C3 H8 O3 PEDCQBHIVMGVHV-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.01 Å
• R-Value Free: 0.212 
• R-Value Work: 0.180 
• Space Group: P 1 2₁ 1

Unit Cell:

Length (Å)	Angle (°)
a = 44.362	α = 90.00
b = 57.143	β = 110.42
c = 60.996	γ = 90.00

Software Package:

Software Name	Purpose
d*TREK	data reduction
REFMAC	refinement
MOLREP	phasing
SCALEPACK	data scaling
PDB_EXTRACT	data extraction
d*TREK	data scaling
HKL-2000	data scaling
CrystalClear	data collection

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2012-06-29 
• Released Date: 2012-07-25 
• Deposition Author(s): Bandaranayake, R.M., Hubbard, S.R.

Revision History 

• Version 1.0: 2012-07-25
  Type: Initial release
• Version 1.1: 2012-08-08
  Type: Database references
• Version 1.2: 2012-08-22
  Type: Database references